Core Viewpoint - A class action lawsuit has been filed against Telix Pharmaceuticals Limited for allegedly making false and misleading statements regarding its prostate cancer therapeutic candidates and supply chain quality, leading to investor losses during the specified class period [3][7]. Allegation Details - The lawsuit claims that defendants materially overstated the progress of Telix's prostate cancer therapeutic candidates [3]. - It is alleged that the quality of Telix's supply chain and partners was also overstated [3]. - As a result, statements made by the defendants about Telix's business, operations, and prospects were materially false and misleading, lacking a reasonable basis [3]. Next Steps - Investors who purchased or acquired Telix shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is January 9, 2026 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across state and federal courts [5]. - The firm has offices in New York, California, and South Carolina [5].
TELIX URGENT CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Limited Stockholders to Contact the Firm Regarding Their Rights Before January 9th